Cellectar Biosciences Inc’s filing revealed that its Chief Executive Officer CARUSO JAMES V acquired Company’s shares for reported $49900.0 on Jul 02 ’25. In the deal valued at $4.99 per share,10,000 shares were bought. As a result of this transaction, CARUSO JAMES V now holds 11,638 shares worth roughly $56677.06.
Then, Longcor Jarrod bought 10,000 shares, generating $49,900 in total proceeds. Upon buying the shares at $4.99, the Chief Operating Officer now owns 12,768 shares.
Before that, Kolean Chad J bought 5,000 shares. Cellectar Biosciences Inc shares valued at $24,950 were divested by the Chief Financial Officer at a price of $4.99 per share. As a result of the transaction, Kolean Chad J now holds 6,418 shares, worth roughly $31255.66.
A number of analysts have revised their coverage, including Oppenheimer’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. ROTH Capital started covering the stock on September 13, 2019. It rated CLRB as “a Buy”.
Price Performance Review of CLRB
On Friday, Cellectar Biosciences Inc [NASDAQ:CLRB] saw its stock jump 3.84% to $4.87. Over the last five days, the stock has lost -0.20%. Cellectar Biosciences Inc shares have fallen nearly -92.62% since the year began. Nevertheless, the stocks have fallen -45.71% over the past one year. While a 52-week high of $68.70 was reached on 06/04/25, a 52-week low of $4.11 was recorded on 08/20/25.
Levels Of Support And Resistance For CLRB Stock
The 24-hour chart illustrates a support level at 4.54, which if violated will result in even more drops to 4.22. On the upside, there is a resistance level at 5.08. A further resistance level may holdings at 5.30.
How much short interest is there in Cellectar Biosciences Inc?
A steep rise in short interest was recorded in Cellectar Biosciences Inc stocks on 2025-08-15, growing by 27517.0 shares to a total of 94417.0 shares. Yahoo Finance data shows the prior-month short interest on 2025-07-15 was 66900.0 shares. There was a rise of 29.14%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2016 when Ladenburg Thalmann began covering the stock and recommended ‘”a Buy”‘ rating along with a $2.70 price target.
